Rezolute Inc (RZLT)

Mar 26, 2025, 7:30 AM EDT - 24 days ago

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Feb 18, 2025, 1:30 AM EST - 2 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 12, 2025, 4:05 PM EST - 2 months ago

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 4, 2025, 8:00 AM EST - 2 months ago

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Jan 31, 2025, 8:00 AM EST - 2 months ago

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Dec 5, 2024, 8:00 AM EST - 4 months ago

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2024, 3:56 PM EST - 4 months ago

Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market

Sep 19, 2024, 4:05 PM EDT - 7 months ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 9, 2024, 10:41 AM EDT - 7 months ago

FDA Gives Green Signal To Rezolute's Genetic Disorder Treatment

Sep 9, 2024, 7:47 AM EDT - 7 months ago

US FDA lifts partial clinical hold on Rezolute's blood sugar treatment

Sep 9, 2024, 7:30 AM EDT - 7 months ago

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Aug 5, 2024, 7:30 AM EDT - 9 months ago

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Jun 27, 2024, 8:00 AM EDT - 10 months ago

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 24, 2024, 8:00 AM EDT - 10 months ago

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Jun 13, 2024, 11:30 PM EDT - 11 months ago

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Jun 13, 2024, 4:01 PM EDT - 11 months ago

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 30, 2024, 8:00 AM EDT - 11 months ago

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 21, 2024, 4:05 PM EDT - 11 months ago

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 15, 2024, 4:05 PM EDT - 1 year ago

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

Mar 6, 2024, 7:30 AM EST - 1 year ago

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Feb 13, 2024, 4:05 PM EST - 1 year ago

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Jan 24, 2024, 8:00 AM EST - 1 year ago

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

Jan 23, 2024, 8:00 AM EST - 1 year ago

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Dec 14, 2023, 8:00 AM EST - 1 year ago

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

Dec 13, 2023, 8:00 AM EST - 1 year ago

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

Nov 24, 2023, 11:14 AM EST - 1 year ago

Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"

Nov 17, 2023, 8:00 AM EST - 1 year ago

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Nov 13, 2023, 4:05 PM EST - 1 year ago

Rezolute Reports First Quarter Fiscal 2024 Results

Nov 9, 2023, 6:57 PM EST - 1 year ago

Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism

Sep 14, 2023, 4:05 PM EDT - 1 year ago

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Sep 6, 2023, 7:00 AM EDT - 1 year ago

Rezolute to Participate in Upcoming Investor Conferences in September

Jun 27, 2023, 4:05 PM EDT - 1 year ago

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Jun 1, 2023, 12:45 PM EDT - 2 years ago

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

OCS

May 11, 2023, 4:05 PM EDT - 2 years ago

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

Mar 23, 2023, 4:50 PM EDT - 2 years ago

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

Mar 8, 2023, 7:00 AM EST - 2 years ago

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Feb 10, 2023, 4:05 PM EST - 2 years ago

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

Dec 15, 2022, 7:00 AM EST - 2 years ago

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

Nov 9, 2022, 4:05 PM EST - 2 years ago

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

Nov 1, 2022, 7:00 AM EDT - 2 years ago

Rezolute to Present at the Jefferies London Healthcare Conference

Oct 20, 2022, 7:00 AM EDT - 2 years ago

Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting

Sep 15, 2022, 4:05 PM EDT - 2 years ago

Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

Sep 7, 2022, 7:00 AM EDT - 2 years ago

Rezolute Announces Presentation at the 60th Annual ESPE Meeting

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

May 12, 2022, 4:05 PM EDT - 3 years ago

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

May 4, 2022, 4:01 PM EDT - 3 years ago

Rezolute to Host Corporate Update Call on May 4, 2022

May 4, 2022, 9:33 AM EDT - 3 years ago

Rezolute, Inc. Announces Closing of Registered Direct Offering